Targets › ACLY
1 program from 1 company in 5 trials: 2 Phase 4, 2 Phase 2, 1 Phase 3; Cardiovascular, Genitourinary, Immunology.
Catalyzes the cleavage of citrate into oxaloacetate and acetyl-CoA, the latter serving as common substrate in multiple biochemical reactions in protein, carbohydrate and lipid metabolism. (UniProt, P53396)
Open in Phaseline: the race on ACLY, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gan & Lee Pharmaceuticals. | Bempedoic Acid ATP-citrate synthase inhibitor | ACLY | Phase 3 | Primary Hyperlipidemia; Acute Coronary Syndromes; Rheumatoid Arthritis (RA); Dyslipidemias … | – |
Primary Hyperlipidemia (1) Acute Coronary Syndromes (1) Rheumatoid Arthritis (RA) (1) Dyslipidemias (1) ADPKD (Autosomal Dominant Polycystic Kidney Disease) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.